Quest Diagnostics Incorporated
DGX
Classement en actions
#929
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus,... Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Prix de l'action
$236.69
Capitalisation boursière
$26.12B
Changement (1 jour)
0.80%
Changement (1 an)
24.31%
Pays
US
Échange Quest Diagnostics Incorporated (DGX)
Catégorie
Healthcare
Bénéfices pour Quest Diagnostics Incorporated (DGX)
Bénéfices en Jun 2026 TTM : $1.42B
Selon les derniers rapports financiers de Quest Diagnostics Incorporated, les bénéfices actuels de l'entreprise sont de $1.42B. En 2024, l'entreprise a réalisé un bénéfice de $1.19B, une augmentation par rapport à celui de 2023 qui était de $1.16B. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Quest Diagnostics Incorporated de 2000 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $1.42B | 4.34% |
| 2025 | $1.36B | 13.90% |
| 2024 | $1.19B | 3.29% |
| 2023 | $1.16B | -9.62% |
| 2022 | $1.28B | -52.22% |
| 2021 | $2.68B | 36.65% |
| 2020 | $1.96B | 72.90% |
| 2019 | $1.13B | 22.35% |
| 2018 | $926.00M | -10.10% |
| 2017 | $1.03B | -5.16% |
| 2016 | $1.09B | -1.54% |
| 2015 | $1.10B | 29.92% |
| 2014 | $849.00M | -37.02% |
| 2013 | $1.35B | 26.17% |
| 2012 | $1.07B | 24.77% |
| 2011 | $856.30M | -27.70% |
| 2010 | $1.18B | -3.55% |
| 2009 | $1.23B | 20.50% |
| 2008 | $1.02B | 11.68% |
| 2007 | $912.40M | -11.70% |
| 2006 | $1.03B | 13.49% |
| 2005 | $910.45M | 9.02% |
| 2004 | $835.13M | 13.19% |
| 2003 | $737.80M | 36.03% |
| 2002 | $542.38M | 63.07% |
| 2001 | $332.60M | 65.49% |
| 2000 | $200.98M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $7.61B | 436.22% |
US
|
|
| $4.76B | 235.59% |
US
|
|
| $-252.70M | -117.81% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 16.84% |
US
|
